Myc confers androgen-independent prostate cancer cell growth. - Wikidata - awgldk - TriplyDB

Myc confers androgen-independent prostate cancer cell growth.

Myc confers androgen-independent prostate cancer cell growth.

http://www.wikidata.org/entity/Q40271517

about

Isosilybin B causes androgen receptor degradation in human prostate carcinoma cells via PI3K-Akt-Mdm2-mediated pathway Regulation of ploidy and senescence by the AMPK-related kinase NUAK1 Stable expression of constitutively-activated STAT3 in benign prostatic epithelial cells changes their phenotype to that resembling malignant cells Growth inhibition and apoptosis induced by daunomycin-conjugated triplex-forming oligonucleotides targeting the c-myc gene in prostate cancer cells The many faces of neuroendocrine differentiation in prostate cancer progression Overexpression of CD24, c-myc and phospholipase 2A in prostate cancer tissue samples obtained by needle biopsy The use of whole genome amplification to study chromosomal changes in prostate cancer: insights into genome-wide signature of preneoplasia associated with cancer progression.Genetic and genomic analysis modeling of germline c-MYC overexpression and cancer susceptibility Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice.Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulation HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle network.The role of mRNA splicing in prostate cancer.Hydrogen sulfide represses androgen receptor transactivation by targeting at the second zinc finger module.Epithelial mesenchymal transition (EMT) in prostate growth and tumor progression Epigenetics of prostate cancer: beyond DNA methylation SKP2 oncogene is a direct MYC target gene and MYC down-regulates p27(KIP1) through SKP2 in human leukemia cells.A long noncoding RNA connects c-Myc to tumor metabolism.Troglitazone suppresses c-Myc levels in human prostate cancer cells via a PPARγ-independent mechanism Androgen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc.The evolutionary history of lethal metastatic prostate cancer.Epigenetics in prostate cancer.Activation of beta-Catenin in mouse prostate causes HGPIN and continuous prostate growth after castration NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies.Genomics of prostate cancer: is there anything to "translate"?The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides In Vitro and In Vivo.The enzymatic activity of apoptosis-inducing factor supports energy metabolism benefiting the growth and invasiveness of advanced prostate cancer cells.Sensitivity and mechanisms of taxol-resistant prostate adenocarcinoma cells to Vernonia amygdalina extract Androgen receptor (AR) suppresses normal human prostate epithelial cell proliferation via AR/β-catenin/TCF-4 complex inhibition of c-MYC transcription.SREBP-2 promotes stem cell-like properties and metastasis by transcriptional activation of c-Myc in prostate cancer c-MYC-induced sebaceous gland differentiation is controlled by an androgen receptor/p53 axis Advancing precision medicine for prostate cancer through genomics.Oncogenic activation of androgen receptor.Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells.Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells.Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches.Systemic GLIPR1-ΔTM protein as a novel therapeutic approach for prostate cancer.Therapeutic Approaches Targeting MYC-Driven Prostate Cancer Androgen receptor differentially regulates the proliferation of prostatic epithelial cells in vitro and in vivo.Disruption of prostate epithelial differentiation pathways and prostate cancer development.

P2860

Q24309684-49D43675-C8C6-494C-8BF8-C25E8B6B971A Q24318723-CEC6D9EA-2465-4901-AA23-EF758B6F1A56 Q24795887-8D85B2E9-3EE7-44C8-B40D-505ADA2C7370 Q25257791-DAE1DFFD-2DE5-4F1B-AC9B-835CD7586F76 Q26992049-A946EA79-FDC3-4871-A4B7-04E8AA8BF022 Q28292092-EF216357-992F-4687-8052-CD3762374286 Q33238054-B28D3E14-6A2A-40A4-828D-AF0232FE157A Q33314433-6AA28401-8D69-4665-A111-3A434C606C1B Q33338530-35E7886C-1E60-4DB2-BF4D-3B83510EF557 Q33390573-6CE41760-DA7E-4D3D-A552-0F1F3DB8ACC1 Q33623369-45C8967D-C057-48F7-8BA8-61889218094B Q33922376-4EE82EC2-60AF-44D8-B858-C1705CF3EE8B Q33947136-AE262BDC-BE61-4ED8-ACAC-3A559018CC73 Q34397291-12EAFB36-35A2-43C7-9CBE-A78154243C91 Q34505232-42E0DBD6-0CC9-450E-9742-046C977ED398 Q34685327-AD0C62BD-69F1-426F-BE86-7F4EDA9D9339 Q34830610-4283583A-309B-4668-81CD-F1E15637552E Q35124419-1C9BB818-C1B0-4EC4-B4FC-4F38865D6F64 Q35434843-0783B759-3AFF-4C5A-8497-5EE2426F45EB Q35548366-89ABC49A-9C55-4B3C-B5BA-CD0F0D1BD4B5 Q35608952-0E81A1F9-D47D-4367-82FA-96BF994C7354 Q35624078-56F704C7-6DC2-43C3-B397-05A2A14113D9 Q36216457-DEAC59D6-4C4B-493B-B612-041AFB9D624E Q36272854-147D588F-2C95-4D60-8092-DFC5C4379AB3 Q36358322-4ADC5754-0487-4559-B3DB-5CF413CFBC97 Q36359489-826998BB-5172-432B-A7E5-7BF38A1C162E Q36481896-B5F8AAFF-469B-4C63-8314-0824D3D97E17 Q36840555-8BD74982-8816-47B8-859F-E60A94BDD594 Q36867637-51063CCE-E90B-45D4-B323-A90FAFD7166F Q37022317-7393307C-D3EA-4908-A8B3-71A223DDF093 Q37187309-43219022-404A-47B9-8508-7E1F7981B9E2 Q37255151-3D8EE63A-1DC8-4ACC-91F1-584BDAA45784 Q37359265-74DDB8D2-0454-4E0A-9110-F015BF17B5BA Q37394982-B6198911-8469-4DED-871C-73A378D5C933 Q37463725-BABA2EBF-F588-42AE-A582-738B889D667A Q37537958-59FF6FBF-DEAC-4369-9060-723B97CF5042 Q37618071-CD1224B9-074A-4126-AB9A-0F6835B5B8C3 Q37676253-51D6D6E0-EEC5-4A76-BF16-BBD00C233E6F Q37688544-B103A5FB-53A8-44BD-A268-D322B3038DC2 Q38160495-8BE7E8F3-0325-40CB-A74B-E844297559A0

P2860

Myc confers androgen-independent prostate cancer cell growth.

http://www.wikidata.org/entity/Q40271517

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

2003年论文

@zh

2003年论文

@zh-cn

name

Myc confers androgen-independent prostate cancer cell growth.

@en

type

label

Myc confers androgen-independent prostate cancer cell growth.

@en

prefLabel

Myc confers androgen-independent prostate cancer cell growth.

@en

P1433

Q40271517-62B6C2CE-3B0A-41F3-9ADB-83AB95BD20A7

P1476

Q40271517-470A7EDA-47C6-4362-83AD-82A560D9BE2F

P2093

Q40271517-3B101A6C-8CB9-4DC1-8E09-052E1858971D

Q40271517-8A27C800-3EC6-44DD-9176-8B2E9A9CB703

Q40271517-A735962E-EE11-45F6-96E5-0E177DD825E5

Q40271517-D2214A74-A359-4CBB-998E-D5B2C87F95C2

P2860

Q40271517-013DC487-95EA-4A6F-8906-F6B24EA00692

Q40271517-046F0DC5-9A7A-4530-94DF-A0D33F811A21

Q40271517-0EC46D70-7110-4AF7-80B2-D9AD9597B04B

Q40271517-19832488-8051-43DA-8AF3-7D8B3AE013B0

Q40271517-340E79B4-E902-4DEC-9C9F-0324C6B35005

Q40271517-3ACD1438-4A42-4963-9F81-0CC6BF6B6A78

Q40271517-5E2477A4-83E3-4681-86FB-55B6C148DEC1

Q40271517-5F09E071-418C-42B0-B60E-D830C428F34C

Q40271517-65DF8440-BFB2-456E-AAA5-759682B32656

Q40271517-72126152-81D6-472D-88DE-A10083F841AA

P304

Q40271517-3B985E0D-6FE8-4760-888A-59C42802D022

P31

Q40271517-D42A6DBE-9062-4BE9-A83F-3FCA83E23321

P356

Q40271517-DE229981-810A-4912-8621-835916BDD8AB

P407

Q40271517-F091891D-381F-4F82-8BE3-6C7F0FFFC6F9

P433

Q40271517-B4F3CA21-0B2A-4C9F-BC70-D447C334B900

P478

Q40271517-61BD602D-1194-449C-BF53-80B3A0B59BF0

P577

Q40271517-8B8F4466-6219-44C5-A352-A85481D787DC

P698

Q40271517-06AC8A9D-755D-47B4-A26B-CBAB024630D7

P932

Q40271517-FF8B4D85-67B2-41A0-9E69-646D2D6DEFE8

P356

P1433

Journal of Clinical Investigation

P1476

Myc confers androgen-independent prostate cancer cell growth.

@en

P2093

Albin Pourtier-Manzanedo

http://www.w3.org/2001/XMLSchema#string

David Bernard

http://www.w3.org/2001/XMLSchema#string

David H Beach

http://www.w3.org/2001/XMLSchema#string

Jesús Gil

http://www.w3.org/2001/XMLSchema#string

P2860

Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor

The ornithine decarboxylase gene is a transcriptional target of c-Myc

From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells

SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27

Mutation of the MXI1 gene in prostate cancer

Myc activates telomerase

Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist

The development of androgen-independent prostate cancer

A genetic screen to identify genes that rescue the slow growth phenotype of c-myc null fibroblasts.

MYC oncogenes and human neoplastic disease.

P304

1724-1731

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI200319035

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

112

http://www.w3.org/2001/XMLSchema#string

P577

2003-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14660748

http://www.w3.org/2001/XMLSchema#string

P932

281646

http://www.w3.org/2001/XMLSchema#string